Core Vct I Share Discussion Threads

[3rd eye] 28/12/2017 16:21

GAW GamesWorkshop breaks out YET again and Ive lost count this year how many times it says its going to beat expectations. Stock trades on P/E rating of 16.2 to 2018 and forecast EPS increase is a walloping 61.3%. They report again on 9th JAN. Certainly worth a punt up to TS.

[argy3] 28/12/2017 15:31

INSP (.09-.10)

Yet another placing soon? Be very careful

[argy3] 28/12/2017 11:54

PREM

Plenty of buys at .352 being shown as sells. This will look cheap on any news.


Unless it's bad of course!

[3rd eye] 28/12/2017 11:34

BOO boohoo.com volume piling in on the BUY side. OK its not cheap but you cant fault online retailing this crimbo according to the media. Not sure when we get the xmas and new year Trading update??? but the chart looks Bullish. Nice contra uptrend developed, 210p share price Target first up.

[3rd eye] 28/12/2017 11:34

BOO boohoo.com volume piling in on the BUY side. OK its not cheap but you cant fault online retailing this crimbo according to the media. Not sure when we get the xmas and new year Trading update??? but the chart looks Bullish. Nice contra uptrend developed, 210p share price Target first up.

[argy3] 28/12/2017 11:12

AMP

MTFB climbing which is good news for AMP

[cpap man] 28/12/2017 09:48

LEG



Perhaps just perhaps LEG might well be one of the main TIPS for 2018?!?!?

[eye2] 28/12/2017 09:40

88E 10% blue

[3rd eye] 28/12/2017 09:37

GFM Griffin Minning a clear breakout on the chart this morning and trades on a low P/E of 7.9 to 2018. Another play on Electric cars.

Date Broker New target Recomm.
15 Dec Cantor...166.00 Buy 😀😎

[3rd eye] 28/12/2017 09:36

GFM Griffin Minning a clear breakout on the chart this morning and trades on a low P/E of 7.9 to 2018. Another play on Electric cars.

Date Broker New target Recomm.
15 Dec Cantor...166.00 Buy 😀😎

[cpap man] 28/12/2017 09:30

LEG



Perhaps just perhaps LEG might well be one of the main TIPS for 2018?!?!?

[cpap man] 28/12/2017 09:25

C*NT:RTW

[STRONG SELL]

[cpap man] 28/12/2017 09:17

NASDAQ:GALT

[hottingup] 27/12/2017 20:58

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

[3rd eye] 27/12/2017 14:55

BUR buample from ford Capital looks interesting technically and got a good write up on
ample from Edmond Jackson | Sun, 24th December 2017 - 12:00....Ive taken a chunk just ove a hour ago.


Burford Capital


I drew attention to this AIM-listed litigation finance specialist (BUR) at 123p in 2015: a “special situation” since legal funding is independent of business cycles, Burford was evolving as a market-leader (principally a US-based firm) yet its shares were below-radar. In a habit of nearly doubling annual profits, at 570p last December it appeared well-placed for 2017 and has maintained its soaring chart to a recent high of 1244p, currently 1125p where it trades on a forward P/E in the mid-twenties, yielding 0.8%. I’d expect consolidation from here given the story is now better-known and new investors may not appreciate how lumpy, litigation finance profits can be; also there is no meaningful yield despite progressive dividends, in support. Yet in the long run Burford is prime-positioned in an international growth industry that's more stable than retail fashion or technology. Yes its stock appears to reflect animal spirits of a mature bull market, and is exposed to a market slide, but would then be a priority to buy/add. The chief risk would be an extensive falling out among senior management, that fragments the firm with key talent leaving – but there’s no such sign as yet. Buy on weakness.

[3rd eye] 27/12/2017 14:54

BUR buample from ford Capital looks interesting technically and got a good write up on
ample from Edmond Jackson | Sun, 24th December 2017 - 12:00....Ive taken a chunk just ove a hour ago.


Burford Capital


I drew attention to this AIM-listed litigation finance specialist (BUR) at 123p in 2015: a “special situation” since legal funding is independent of business cycles, Burford was evolving as a market-leader (principally a US-based firm) yet its shares were below-radar. In a habit of nearly doubling annual profits, at 570p last December it appeared well-placed for 2017 and has maintained its soaring chart to a recent high of 1244p, currently 1125p where it trades on a forward P/E in the mid-twenties, yielding 0.8%. I’d expect consolidation from here given the story is now better-known and new investors may not appreciate how lumpy, litigation finance profits can be; also there is no meaningful yield despite progressive dividends, in support. Yet in the long run Burford is prime-positioned in an international growth industry that's more stable than retail fashion or technology. Yes its stock appears to reflect animal spirits of a mature bull market, and is exposed to a market slide, but would then be a priority to buy/add. The chief risk would be an extensive falling out among senior management, that fragments the firm with key talent leaving – but there’s no such sign as yet. Buy on weakness.

[3rd eye] 27/12/2017 11:53

FEVR Fevertee Drinks ..breaking out through the down trend channel and momentum fully behind it. Reported XMAS trad update 25th January last year. Should get an update on the refocusing on the US market.